Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer.

Genetic Vaccines and Therapy Pub Date : 2004-08-25 eCollection Date: 2004-01-01 DOI:10.1186/1479-0556-2-12
Srinivas Nagaraj, Carsten Ziske, Ingo Gh Schmidt-Wolf
{"title":"Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer.","authors":"Srinivas Nagaraj,&nbsp;Carsten Ziske,&nbsp;Ingo Gh Schmidt-Wolf","doi":"10.1186/1479-0556-2-12","DOIUrl":null,"url":null,"abstract":"<p><p>Modulation of the immune system by genetically modified immunological effector cells is of potential therapeutic value in the treatment of malignancies. Interleukin-2 (IL-2) is a crucial cytokine which induces potent antitumor response. Cytokine-induced killer cells (CIK) have been described as highly efficient cytotoxic effector cells capable of lysing tumor cell targets and are capable of recognizing these cells in a non-MHC restricted fashion. Dendritic cells (DC) are the major antigen presenting cells. This study evaluated the antitumor effect of CIK cells which were non-virally transfected with IL-2 and co-cultured with pulsed and unpulsed DC. Human CIK cells generated from peripheral blood were transfected <i>in vitro</i> with plasmid encoding for the human IL-2. Transfection involved a combination of electrical parameters and a specific solution to deliver plasmid directly to the cell nucleus by using the Nucleofector<sup>®</sup> electroporation system. Nucleofection resulted in the production of IL-2 with a mean of 478.5 pg/10<sup>6</sup> cells (range of 107.6-1079.3 pg /10<sup>6</sup> cells/24 h) compared to mock transfected CIK cells (31 pg/10<sup>6</sup> cells) (<i>P</i> = 0.05). After co-culturing with DC their functional ability was assessed <i>in vitro</i> by a cytotoxicity assay. On comparison with non-transfected CIK cells co-cultured with DCs (36.5 ± 5.3 %), transfected CIK cells co-cultured with DC had a significantly higher lytic activity of 58.5 ± 3.2% (<i>P</i> = 0.03) against Dan G cells, a human pancreatic carcinoma cell line.</p>","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"2 ","pages":"12"},"PeriodicalIF":0.0000,"publicationDate":"2004-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-2-12","citationCount":"34","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic Vaccines and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1479-0556-2-12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2004/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 34

Abstract

Modulation of the immune system by genetically modified immunological effector cells is of potential therapeutic value in the treatment of malignancies. Interleukin-2 (IL-2) is a crucial cytokine which induces potent antitumor response. Cytokine-induced killer cells (CIK) have been described as highly efficient cytotoxic effector cells capable of lysing tumor cell targets and are capable of recognizing these cells in a non-MHC restricted fashion. Dendritic cells (DC) are the major antigen presenting cells. This study evaluated the antitumor effect of CIK cells which were non-virally transfected with IL-2 and co-cultured with pulsed and unpulsed DC. Human CIK cells generated from peripheral blood were transfected in vitro with plasmid encoding for the human IL-2. Transfection involved a combination of electrical parameters and a specific solution to deliver plasmid directly to the cell nucleus by using the Nucleofector® electroporation system. Nucleofection resulted in the production of IL-2 with a mean of 478.5 pg/106 cells (range of 107.6-1079.3 pg /106 cells/24 h) compared to mock transfected CIK cells (31 pg/106 cells) (P = 0.05). After co-culturing with DC their functional ability was assessed in vitro by a cytotoxicity assay. On comparison with non-transfected CIK cells co-cultured with DCs (36.5 ± 5.3 %), transfected CIK cells co-cultured with DC had a significantly higher lytic activity of 58.5 ± 3.2% (P = 0.03) against Dan G cells, a human pancreatic carcinoma cell line.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人类细胞因子诱导的杀伤细胞通过非病毒白介素-2基因转移增强了体外细胞溶解活性。
通过基因修饰的免疫效应细胞调节免疫系统在恶性肿瘤的治疗中具有潜在的治疗价值。白细胞介素-2 (IL-2)是一种重要的细胞因子,可诱导有效的抗肿瘤反应。细胞因子诱导杀伤细胞(CIK)是一种高效的细胞毒性效应细胞,能够裂解肿瘤细胞靶点,并能够以非mhc限制的方式识别这些细胞。树突状细胞(DC)是主要的抗原呈递细胞。本研究评价了用IL-2非病毒转染CIK细胞,并与脉冲和非脉冲DC共培养CIK细胞的抗肿瘤作用。用编码人IL-2的质粒转染人外周血CIK细胞。转染包括电参数和特定溶液的组合,通过使用nucleoector®电穿孔系统将质粒直接传递到细胞核。与模拟转染CIK细胞(31 pg/106细胞)相比,核转染导致IL-2的产生平均为478.5 pg/106细胞(范围为107.6-1079.3 pg/106细胞/24 h) (P = 0.05)。在与DC共培养后,通过细胞毒性试验评估其体外功能能力。与未转染DC的CIK细胞(36.5±5.3%)相比,转染DC的CIK细胞对人胰腺癌细胞株Dan G细胞的裂解活性显著提高(58.5±3.2%)(P = 0.03)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Retraction: Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan. DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand? Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model. Targeting wild-type Erythrocyte receptors for Plasmodium falciparum and vivax Merozoites by Zinc Finger Nucleases In- silico: Towards a Genetic Vaccine against Malaria. A brief review on dengue molecular virology, diagnosis, treatment and prevalence in Pakistan.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1